StockData
RGCNasdaqMedicinal Chemicals & Botanical Products

Regencell Bioscience Holdings Ltd

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026
$10.05+0.46 (+4.80%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Regencell Bioscience has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Regencell Bioscience filed with the SEC